Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.
about
Panobinostat for the treatment of multiple myeloma: the evidence to dateHistone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancyA phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review.New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.Marine-derived angiogenesis inhibitors for cancer therapy.Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors.Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and PanobinostatThe role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma.Management of double-refractory multiple myeloma.The role of epigenetics in the biology of multiple myeloma.Current and potential epigenetic targets in multiple myeloma.Molecularly targeted therapies in multiple myelomaPanobinostat: a review of trial results and future prospects in multiple myeloma.Panobinostat: first global approval.Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma.Histone deacetylase inhibitors in multiple myeloma: from bench to bedside.In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testingPooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma.Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma.
P2860
Q26778674-42EF5964-3591-47E9-9FA2-24B0FDFB1693Q28082536-08E2972A-C5E3-405F-B7D1-A133FB414907Q33410997-6E6B6855-942C-40F9-80DC-4E075FDAB7EBQ33432845-80E8B266-0795-4758-9A92-EF1FA2A7A7FAQ34224278-C6D1E09B-847C-496A-959B-715BCE877577Q34602263-F3A98C9D-8A6F-415F-A474-F9880FFAD1DCQ34773850-FC6A0DBF-6331-4113-B872-D06D43DF9117Q36994177-EB6DF076-1B0B-4E58-9E22-859B62F86CB3Q37083880-FCD7E8DD-2D4B-41B6-9581-FF9DF2BBE3DBQ37199772-7FB64938-2D2C-4893-8058-6E0441BA2E46Q38101381-969234D1-06ED-48EF-A116-5D519132C878Q38131456-87883279-FBBF-48D3-824A-E07A3ADE8D53Q38208520-F45A99F1-7C9F-458C-BD22-1E5AE0D14296Q38210475-436D90D3-3AC3-4D99-B37F-B8CB6FF2C75CQ38211866-AA874AAD-6580-4570-969D-01E5BF1F15F7Q38269612-5D04E5DF-8526-4BF3-B0CB-91784DC3DB8FQ38403118-09857709-92B2-410F-8B3D-0D344E79CAE8Q38716460-F3F64ADE-0234-4718-8B1C-0622C40D69FFQ38813504-4F9516B8-8CD8-4AA7-B113-BAE835A134BFQ38910971-41C6CE8E-CDD1-4D92-9E8E-08EC94C4F3C1Q39177792-1159E499-8970-4843-A008-7AF86FD16838Q41088379-FA37EA79-377F-4BC4-90D4-0BD4303B80F8Q41346803-95FE4D44-6C19-49A5-9C54-C301AB2CE2C0Q42425704-EBEF0587-B3BE-4526-B99F-4E81BB4E1F78Q50166078-BE2F6B1D-0755-4B5A-8AF3-269386E7D1C4
P2860
Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Phase II study of melphalan, t ...... d/refractory multiple myeloma.
@ast
Phase II study of melphalan, t ...... d/refractory multiple myeloma.
@en
type
label
Phase II study of melphalan, t ...... d/refractory multiple myeloma.
@ast
Phase II study of melphalan, t ...... d/refractory multiple myeloma.
@en
prefLabel
Phase II study of melphalan, t ...... d/refractory multiple myeloma.
@ast
Phase II study of melphalan, t ...... d/refractory multiple myeloma.
@en
P2093
P2860
P50
P1433
P1476
Phase II study of melphalan, t ...... d/refractory multiple myeloma.
@en
P2093
Anna Marina Liberati
Claudia Polloni
Francesco Alesiani
Laura Corvatta
Mario Boccadoro
Massimo Catarini
Patrizia Caraffa
Pietro Leoni
Silvia Gentili
Stefano Pulini
P2860
P304
P356
10.3109/10428194.2012.664844
P577
2012-03-16T00:00:00Z